ReviewNPJ Parkinson's disease2016
Cognitive decline in Parkinson's disease: the complex picture.
Review in NPJ Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Resting-state EEG changes associated with cognitive decline in Parkinson's disease: a systematic review.Journal of neural transmission (Vienna, Austria : 1996) · 2026Pooled it
- Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations.Movement disorders : official journal of the Movement Disorder Society · 2025Pooled it
- Does transcranial direct current stimulation enhance cognitive performance in Parkinson's disease mild cognitive impairment? An event-related potentials and neuropsychological assessment study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Trial
- Trial
- A Comparison of Machine Learning Models for Classification of Parkinson's Disease During a Working Memory and Sustained Attention Task.Brain sciences · 2026Article
- Development and Preliminary Validation of ORCA-PD, an Online Rapid Cognitive Assessment for Parkinson Disease: Mixed Methods Study.Journal of medical Internet research · 2026Article
- APOE, Aβ42, and tau differentially impact cognitive decline in Sporadic, GBA1 and LRRK2 Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Article
- Altered cerebrovascular haemodynamics in Parkinson's disease: Insights from 4D flow MRI.NPJ Parkinson's disease · 2026Article
- New Challenges in the Study of Cognitive Impairment in Parkinson's Disease.Brain sciences · 2025Article
- Structural and diffusion imaging in olfactory-related brain regions in Parkinson's disease: predictors of clinical progression.Scientific reports · 2025Article
- Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations.Movement disorders : official journal of the Movement Disorder Society · 2025Review
- Unraveling morphological brain network disparities Parkinsonian tremor from essential tremor: an artificial intelligence approach for clinical differentiation.NPJ Parkinson's disease · 2025Article
- Altered network efficiency in isolated REM sleep behavior disorder: A multicentric study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- AI-Driven Advances in Parkinson's Disease Neurosurgery: Enhancing Patient Selection, Trial Efficiency, and Therapeutic Outcomes.Brain sciences · 2025Review
- Working memory filtering at encoding and maintenance in healthy ageing, Alzheimer's and Parkinson's disease.Scientific reports · 2025Article
- Evaluation of Computer-Based Cognitive Training on Mild Cognitive Impairment in Parkinson's Disease (PD-MCI): Α Review.Journal of clinical medicine · 2025Review
- Clinically probable RBD is an early predictor of malignant non-motor Parkinson's disease phenotypes.NPJ Parkinson's disease · 2025Article
- Subregional analysis of the amygdala, thalamus, and hypothalamus at the pre-decline stage in Parkinson's disease with later cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Diagnostic Value of Carotid Intima-Media Thickness Combined with Periventricular White Matter Hyperintensities for Mild Cognitive Impairment in Parkinson's Disease.Neuropsychiatric disease and treatment · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild cognitive impairment (PD-MCI) and dementia (PDD) are among the most frequent non-motor symptoms in Parkinson's disease (PD). PD-MCI is six times more likely than age-matched controls to develop dementia and the PDD prevalence is 80% after 15-20 years of disease. Therefore, research has focused on the identification of early dementia biomarkers including specific cognitive at-risk profiles hoping to implement therapeutic interventions when they are most likely to be efficacious. However, given the heterogeneous neuropathological, neurochemical, and neuropsychological nature of cognitive deficits, definition of a comprehensive cognitive model of PDD is a challenge. Evidence from neuroimaging studies using different methods and techniques suggests that in addition to degeneration of the dopaminergic system, other mechanisms have a role including β-amyloid and tau deposition, and that specific cognitive scales could help identifying a malignant profile. Prospective studies combining neuroimaging techniques and specific cognitive tests are required to define the interplay between the various neurodegenerative processes and the contribution of structural disconnection in brain functional networks, heralding the development of dementia in PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.